行情

BCLI

BCLI

Brainstorm Cell
NASDAQ

实时行情|Nasdaq Last Sale

4.650
-0.050
-1.06%
盘后: 4.650 0 0.00% 16:00 04/03 EDT
开盘
4.740
昨收
4.700
最高
4.820
最低
4.550
成交量
52.58万
成交额
--
52周最高
10.00
52周最低
3.430
市值
1.30亿
市盈率(TTM)
-4.3967
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BCLI价格均价为11.50,最高价位14.00,最低价为9.00。

EPS

BCLI 新闻

更多
  • 瑞幸是否面临强制退市?中概股赴美IPO将遭更大僵局
  • 新浪美股 · 1小时前
  • “抄底”抄在了“半山腰” 巴菲特抛售航空股
  • 新浪美股 · 1小时前
  • 美媒:传染病专家福奇等人敦促特朗普颁布全国“居家令”
  • 央视 · 2小时前
  • 普京表示俄主张全球能源市场长期稳定
  • 新华网 · 2小时前

所属板块

生物技术和医学研究
-0.74%
制药与医学研究
-0.56%

热门股票

代码
价格
涨跌幅

BCLI 简况

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
展开

微牛提供Brainstorm Cell Therapeutics Inc(NASDAQ-BCLI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BCLI股票新闻,以帮助您做出投资决策。